medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2010, Number 01

<< Back Next >>

Ginecol Obstet Mex 2010; 78 (01)

Effectiveness of two schemes flexible GnRH antagonist ovarian hyperstimulation in cycles of intrauterine more insemination

Barros-Delgadillo JC, Trejo-Castañeda H, E-Ormsby C, Gaviño-Gaviño F

Language: Spanish
References: 32
Page: 15-28
PDF size: 393.09 Kb.


ABSTRACT

Objetive: To compare two flexible protocols of GnRHant in OH plus lUI vs a control group without GnRHant.
Materials and methods: Randomized controlled trial 90 infertile patients were analyzed in 116 cycles of lUI. Cycles were randomized in 3 groups; group 1: started GnRHant when the leading follicle reached 14mm, group 2: when it reached 16mm and group 3: without GnRHant hormonal determinations were done during OH. Main outcomes were: premature LH raise incidence, premature luteinization (PL) and pregnancy rate per cycle.
Results: Premature LH rise incidence was 2.6% (3 cycles) and PL 6% (7 cycles). Group 1 didn’t present cycles with LH rise or PL, groups 2 and 3 presented LH rise in 3.1 % and 1.8% and Pl in 12.5% and 5.4% respectively. Pregnancy rate with GnRHant was 16.4% (95%IC 8.1-28.1) vs. 7.2% (95% Ie 2.0-17.5%) without GnRHant (group 3) (p = 0.16): groups 1 and 2 represented a pregnancy rate of 20.6% (95% IC 7.9-39.7) and 12.5% (95% IC 3.5-28.9%) respectively (p = 0.49). Mature follicles number reached meaning difference between all groups (p = 0.04) specially between groups 1 and 2 (p = 0.02).
Conclusions: A trend to elevate pregnancy rates was observed with GnRHant specially with when it was started when leading follicle reached 14 mm (p › 0.05). Starting GnRHant with 16 mm was not totally usefully to prevent PL.


REFERENCES

  1. The ESHRE Capri Workshop Group. Intrauterine Insemination. Hum Reprod Update 2009;15(3):265-277.

  2. Sánchez I, Amorós D, Lucco F, González S, y col. Inseminación artificial. En: Bellver J, Domingo J, ed. Manual práctico de esterilidad y reproducción humana. Madrid: McGraw-Hill, 2008;p:23-40.

  3. Barros JC, Rojas JC, Molina AC, Villalobos S, y col. Factores pronósticos de embarazo en inseminación intrauterina. Ginecol Obstet Mex 2006;74:611-625.

  4. Bensdorp J, Cohlen BJ, Heineman MJ, et al. Inseminación intrauterina para la subfertilidad masculina. Biblioteca Cochrane Plus, 2008, num. 2 http://www.update-sofwere.com

  5. Cantineau AEP, Cohlen BJ, Heineman MJ. Ovarian stimulations protocols (antioestrogens, gonadotrophins with and without GnRH agonists/antagonists) for intrauterina insemination (IUI) in women with subfertility. Cochrane Database of Systematic Reviews 2008, Issue 2, Art. No CD005356 D0I.

  6. Gómez P, Juliá B, Acevedo M, Martínez M, et al. Timing ovulation for intrauterine insemination with GnRH antagonist Hum Reprod 2005;20(2):368-372.

  7. Kosmas I, Tatsioni A, Kolibianakis E, Verpoest W, et al. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a metaanalysis. Fertil Steril 2008;90:367-372.

  8. Allegra A, Marino A, Coffaro F, Scaglione P, et al. GnRH antagonists-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod 2007;22:101-108.

  9. Cantineau AE, Cohlen BJ. The prevalence and influence of luteinizing hormone surges in stimulation cycles combined with intrauterine insemination during a prospective cohort study. Fertil Steril 2007;88:107-112.

  10. Van Rumste MME, Custers LM, van der Veen F, van Wely, et al. The influence of the number of follicles on pregnancy rates in intrauterine insemination with ovarian stimulation: a metaanalysis. Hum Reprod Update 2008;14:563-570.

  11. Al-Inany HG, About-Setta AM, Aboulghar M. Antagonistas de la hormona liberadora de gonadotrofina para la concepción asistida. En: Biblioteca Cochrane Plus 2008, No 2 http://www.update-sofwere.com.

  12. Ludwing M, Katalinic A, Banz C, Schroeder A, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patient´s needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002;17(11):2842-2845.

  13. Ragni G, Alagna F, Brigante C, Riccaboni A, et al. GnRH antagonists and mild ovarian stimulation for intrauterine insemination: a randomized study comparing different gonadotrophin dosages. Hum Reprod 2004;19:1;54-58.

  14. Lambalk CB, Leader A, Olivennes F, Fluker MR, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results ot a double-blind, placebo-controlled, multicentre trial. Hum Reprod 2006;21:3;632-639.

  15. Crosignani PG, Somigliana E. On behalf of the Intrauterine Insemination Study Group. Effect of GnRH antagonists in FSH midly stimulated intrauterine insemination cycles: a multicentre randomized trial. Hum Reprod 2007;22(2):500-505.

  16. Lee Tsung-Hsien, Lin YuHung, Seow Kok-Min, Hwang Jiann- Loung. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone during controlled ovarian stimulation using letrozole and gonadotropins a randomized trial. Fertil Steril 2008;90(1):113-120.

  17. Gomez P, Acevedo B, Chavez M, Manzanares M, et al. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril 2008;89:620-624.

  18. OMS. Manual de laboratorio para el examen del semen humano y de la interacción entre el semen y el moco cervical. 4a ed. Buenos Aires: Panamericana, 2001.

  19. Revised American Society for Reproductive Medicine classification of endometriosis 1996. Fertil Steril 1997;67:817-821.

  20. Merviel P, Heraud M, Grenier N, Lourdel E, et al. Predictive factors for pregnancy after intrauterine insemination (IUI): An analysis of 1038 cycles and a review of the literature. Fertil Steril 2008 published on line november 2008.

  21. Iberico G, Vioque J, Ariza N, Lozano J, et al. Analysis of factors influencing pregnancy rates in homologous intrauterine insemination. 2004;81(5):1308-1313.

  22. Rohi M, Rasmussen P, Erb K, Broch S, Rex S. Homologous intrauterine insemination. An evaluation of prognostic factors based on a review of 2473 cycles. Acta Obstet Gynecol Scand 2001;80:74-81.

  23. Goverde AJ, Lambalk CB, McDonnell J, Schats R, et al. Further considerations on natural or mild hyperstimulation cycles for intrauterine insemination treatment: effects on pregnancy and multiple pregnancy rates. Hum Reprod 2005;20(11):3141-3146.

  24. Steures P, van der Steeg J, Mol BW. Eijkemans M, et al.CECERM (Collaborative Effort in Clinical Evaluation in Reproductive Medicine) Prediction of an ongoing pregnancy after intrauterine insemination. Fertil Steril 2004;82(1):45-51.

  25. Zikopoulos K, Kaponis A, Adonakis G, Sotiriadis A, et al. A prospective randomized study comparing gonadotropinreleasing hormone agonists or gonadotropin-realising hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia. Fertil Steril 2005;83(5):1354-1362.

  26. Williams S, Hillard J, De Vane G, Yeko I, et al. A randomized, multicenter study comparing the efficacy of recombinant FSH vs recombinant FSH with Ganirelix during superovulationl IUI therapy. Am J Obstet Gynecol 2004;191(2):648-653.

  27. Checa M, Prat M, Robles A, Carreras R. Use of gonadotropinreleasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends. Fertil Steril 2006;85(3):573-577.

  28. Cunha-Filho J. Premature LH and progesterone rise in premature insemination cycles: analysis of related factors. Reproductive BioMedicine Online. www.rbmonline.com/Article 89.

  29. Ragni G, Veggetti W, Baroni E, Colombo M, et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without gonadotrophin releasing hormone antagonists. Hum Reprod 2001;16:2258-2262.

  30. Ragni G, Caliari L, Nicolosi A, Arnoldi M, et al. Preventing highorder multiple pregnancies during controlled ovarian hyperstimulation and intrauterine insemination: 3 year’s experience using Iow dose recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil SteriI 2006;85(3):619-624.

  31. Ertunc D, Tok E, Savas A, Ozturk LL, Dilek S. Gonadotropinreleasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome. Fertil Steril 2009. Published on line February 2009.

  32. Palmer R. Strategies to reduce multiple pregnancy due to ovulation stimulation Fertil SteriI 2009;91:1-17.




2020     |     www.medigraphic.com